Jemperli (dostarlimab-gxly)

P2/3, N=758, Active, not recruiting, GlaxoSmithKline | Phase classification: P3 --> P2/3

P1, N=3, Terminated, University of Iowa | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2024 --> Nov 2025

In endometrial cancer, dostarlimab combined with chemotherapy improved PFS in both dMMR/MSI-H and mismatch repair-proficient disease and increased OS overall...Confidence is strongest for PD-1 inhibitors in MSI-H/dMMR tumors, trastuzumab deruxtecan in HER2-low or HER2-positive cancers, and encorafenib-based regimens in BRAF V600E metastatic colorectal cancer. Implementation should include validated assays (including reconfirmation of HER2 status), prioritize earlier treatment lines where gains are greatest, and require vigilant ILD monitoring. Head-to-head trials and assay standardization, especially for tumor mutational burden, remain priorities.

Current research hotspots regarding immune checkpoint inhibitors in the treatment of endometrial cancer include microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, chemotherapy, pembrolizumab, lenvatinib, and dostarlimab. This study systematically analyzes the current state of research in this field, focusing on research hotspots, emerging trends, and future development directions. Additionally, it comprehensively evaluates the most influential literature, core journals, authoritative scholars, leading research institutions, and major contributing countries in this field.

P2, N=51, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026

P4, N=100, Not yet recruiting, GlaxoSmithKline

P2, N=134, Active, not recruiting, Grupo Español de Investigación en Cáncer de Ovario | Trial primary completion date: Dec 2025 --> Jul 2028 | Trial completion date: Dec 2025 --> Jul 2028

P3, N=88, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Feb 2027 --> Jun 2026

P2, N=351, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Nov 2026

Genetic testing confirmed sensitivity to dostarlimab-gxly and pembrolizumab, leading to the initiation of pembrolizumab (200 mg Q3W) and lenvatinib (20 mg QD) in June 2024 after spine surgery. We present a 57-year-old female patient initially diagnosed with FIGO Stage 2 EC, who subsequently developed distant metastases and was restaged as FIGO Stage 4B recurrent disease. The management of this patient illustrates the multimodal treatment approach and the critical role of molecular subtyping in guiding immunotherapeutic strategies for recurrent advanced EC.

Results from the RUBY and NRG-GY018 trials show that combining dostarlimab or pembrolizumab with platinum-based chemotherapy improves survival in patients with untreated advanced disease...Overcoming this resistance requires combination strategies, such as using anti-angiogenic agents like lenvatinib with immune checkpoint inhibitors, as shown in the KEYNOTE-775 trial...As molecular monitoring via liquid biopsy and the use of antibody-drug conjugates (ADCs) evolve, the personalization of immunotherapy continues to progress. This review examines current clinical evidence and the mechanisms of resistance to define the future of precision medicine in endometrial cancer.

P1/2, N=34, Active, not recruiting, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2027 --> Mar 2027